Nexalin Technology (NXL) Cash from Investing Activities (2023 - 2026)
Nexalin Technology (NXL) posted Cash from Investing Activities of $1.5 million for Q2 2026, down 3.27% on a QoQ basis from $1.5 million in Q1 2026, and up 137.25% year-over-year from $615512.2 in Q2 2025.
Analysis
Nexalin Technology (NXL) Cash from Investing Activities (2023 - 2026) Analysis & Trends
Nexalin Technology has reported Cash from Investing Activities for 4 years, with the latest figure at $1.5 million in Q2 2026.
- On a quarterly basis, Cash from Investing Activities rose 137.25% year-over-year to $1.5 million in Q2 2026; TTM through Jun 2026 was $5.3 million, a 199.66% increase from a year earlier, with the FY2025 full-year figure at -$131991.0, up 77.15% from the prior year.
- Cash from Investing Activities was $1.5 million for Q2 2026 at Nexalin Technology, down from $1.5 million in the prior quarter.
- The five-year high for Cash from Investing Activities was $1.6 million in Q4 2024, with the low at -$4.5 million in Q3 2024.
- Average Cash from Investing Activities over 4 years is $479524.8, with a median of $1.3 million recorded in 2023.
- The sharpest annual moves came in 2024 and 2026: Cash from Investing Activities slumped 639.66% in 2024, then surged 137.25% in 2026.
- Over 4 years, Cash from Investing Activities stood at $1.2 million in 2023, then jumped by 33.09% to $1.6 million in 2024, then plunged by 57.66% to $689180.0 in 2025, then soared by 111.89% to $1.5 million in 2026.
- The last three Cash from Investing Activities figures came in at $1.5 million (Q2 2026), $1.5 million (Q1 2026), and $689180.0 (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Investing Activities (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 179.79 Bn | 174.18 Bn | 7.27 Bn | -673.00 Mn |
| 2 | Intuitive Surgical | 127.69 Bn | 122.47 Bn | 1.96 Bn | -26.60 Mn |
| 3 | Medtronic | 117.23 Bn | 108.41 Bn | 6.34 Bn | -1.62 Bn |
| 4 | Stryker | 103.55 Bn | 100.07 Bn | 4.50 Bn | -639.00 Mn |
| 5 | Boston Scientific | 63.24 Bn | 62.70 Bn | 3.85 Bn | -1.96 Bn |
| 6 | Edwards Lifesciences | 49.97 Bn | 45.72 Bn | 1.35 Bn | -193.20 Mn |
| 7 | Alcon | 32.83 Bn | 31.37 Bn | 1.68 Bn | -222.00 Mn |
| 8 | Dexcom | 32.30 Bn | 30.35 Bn | 830.00 Mn | 329.80 Mn |
| 9 | Steris | 20.73 Bn | 20.25 Bn | 684.20 Mn | -108.50 Mn |
| 10 | Nexalin Technology | 3.44 Mn | 2.44 Mn | 8,897.00 | 1.46 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 1.46 Mn |
| Mar 31, 2026 | 1.51 Mn |
| Dec 31, 2025 | 689,180.00 |
| Sep 30, 2025 | 1.63 Mn |
| Jun 30, 2025 | -3.92 Mn |
| Mar 31, 2025 | 1.47 Mn |
| Dec 31, 2024 | 1.63 Mn |
| Sep 30, 2024 | -4.48 Mn |
| Jun 30, 2024 | 1.55 Mn |
| Mar 31, 2024 | 729,314.00 |
| Dec 31, 2023 | 1.22 Mn |
| Sep 30, 2023 | 830,769.00 |
| Jun 30, 2023 | 872,372.00 |
| Mar 31, 2023 | 1.53 Mn |